CLN-978
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sjögren
Conditions
Sjögren, Sjogren Disease, Sjogren's Syndrome
Trial Timeline
Oct 1, 2025 → Mar 15, 2029
NCT ID
NCT07041099About CLN-978
CLN-978 is a phase 1 stage product being developed by Cullinan Therapeutics for Sjögren. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07041099. Target conditions include Sjögren, Sjogren Disease, Sjogren's Syndrome.
What happened to similar drugs?
0 of 8 similar drugs in Sjögren were approved
Approved (0) Terminated (1) Active (7)
Hype Score Breakdown
Clinical
6
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07041099 | Phase 1 | Recruiting |
| NCT06994143 | Phase 1 | Recruiting |
| NCT06613360 | Phase 1 | Recruiting |
| NCT05879744 | Phase 1 | Active |
Competing Products
20 competing products in Sjögren